Ask any analytical chemist which hyphenated technique has become indispensable over the past decade, and the answer will almost certainly be the same: tandem chromatography–mass spectrometry. Whether it is <a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-lc-ms/ms-analysis">LC–MS/MS</a> quantifying a novel biologic’s metabolic fate, or <a target="_blank" rel="noopener noreferrer" href="https://www.organomation.com/preparing-samples-for-gc-ms/ms-analysis">GC–MS/MS</a> chasing per- and polyfluoroalkyl substances (PFAS) down to sub-part-per-trillion levels in municipal water, the combination of chromatographic separation with the specificity of tandem mass detection has become the analytical workhorse of choice across virtually every regulated sector.Below we examine the key forces propelling this expansion, from biopharma pipeline dynamics and PFAS regulatory mandates to AI-driven automation and reshoring of pharmaceutical manufacturing—and explore what each trend means for laboratories managing sample preparation and analytical workflows.<h3>Biopharma: The Engine Room of LC–MS/MS Demand</h3><h4>GLP-1 Agonists and the Metabolomics Gold Rush</h4>The explosive commercial and scientific interest in GLP-1 receptor agonists—<a target="_blank" rel="noopener noreferrer" href="https://www.sepscience.com/advancing-glp-1-peptide-analysis-chromatography-challenges-and-innovations-12163">semaglutide and related peptide therapeutics </a>for diabetes and obesity—has dramatically expanded the analytical demands placed on tandem MS platforms. Discovery programs require precise quantification of peptide drug candidates and endogenous biomarkers across complex biological matrices. These workflows rely on high-sensitivity LC–MS/MS for pharmacokinetic profiling, receptor occupancy studies, and metabolomics characterization. Metabolomics is, in fact, projected to be the fastest-growing application segment in mass spectrometry, driven in part by its growing role in cancer screening, biomarker discovery, and metabolic disease research.I have been spending more time learning about GLP-1s because this is the hot topic that people want to discuss on the Concentrating on <a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL?si=n9GLz9zjSCOrVfXPxFPhng&amp;nd=1&amp;dlsi=52868e027aad4d22">Chromatography podcast</a>. With that said, I was astounded looking at CNBC.com during breakfast this morning to see that <a target="_blank" rel="noopener noreferrer" href="https://www.cnbc.com/2026/03/21/glp-1-diets-restaurants-protein-fiber-weight-loss-drugs.html">one in eight Americans are currently taking one of these drugs such as Ozempic</a>.<h4>Antibody–Drug Conjugates and Gene Therapy: Complexity at Every Step</h4>The ascent of antibody–drug conjugates (ADCs) and gene therapies has introduced a new level of analytical complexity. ADCs blend the target specificity of monoclonal antibodies with the cytotoxic potency of small-molecule payloads—and characterizing the linker chemistry, drug-to-antibody ratio (DAR), and conjugate stability demands high-resolution LC–MS/MS at every stage from discovery through QC release testing. Gene therapy vectors require equally rigorous characterization of impurities, aggregates, and empty/full capsid ratios.This translates into a direct need for low-evaporation, high-recovery concentration methods that preserve labile protein structures and maintain sample integrity prior to LC–MS/MS injection. <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392">Nitrogen evaporation workflows</a> that minimize oxidative stress and maintain sample temperature are increasingly critical in these pipelines.<h4>Precision Medicine and Multi-Omics Integration</h4>The shift toward precision medicine has accelerated adoption of high-throughput, multi-analyte MS platforms. Proteomics, metabolomics, and lipidomics workflows are converging on a single analytical platform—tandem MS—and generating datasets of a scale and complexity that were unimaginable ten years ago.Make no mistake: the triple quadrupole serves an irreplaceable role in quantitative targeted analysis. At the same time, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products?category=134&amp;manufacturerItems=3">Orbitrap </a>and Q–TOF hybrid platforms are growing rapidly as researchers demand full-scan accurate mass for untargeted discovery.<h3>Environmental Mandates: PFAS Testing Drives Adoption</h3>Environmental testing is something that every person, chemist or not, can understand the importance of. Mounting mandates from the U.S. Environmental Protection Agency and European regulators regarding PFAS—the “forever chemicals” whose extraordinary environmental persistence is matched only by the analytical challenge of detecting them at trace levels—have created immediate, compliance-driven investment in LC–MS/MS infrastructure.<h4>The Regulatory Framework Chemists Need to Know</h4>The EPA has codified a suite of LC–MS/MS-based methods as the analytical standard for PFAS in water and solid matrices:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/epa-533-drying-down-pfas-samples-after-spe">EPA Method 533</a>: Weak anion exchange SPE combined with LC–MS/MS; covers 25 PFAS including short-chain compounds in drinking water.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/sample-concentration-epa-method-537-pfas-determination">EPA Method 537.1</a>: Reversed-phase SPE followed by LC–MS/MS; covers 18 PFAS including the GenX compound, with method detection limits in the low ng/L range.</li><li><a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/en/solutions/environmental/water-testing/pfas-in-water/us-epa-method-8327?srsltid=AfmBOooCY1pcavj7B1PH-75d3HO4BGDglNlhmyTyrpDY3zvUksMO1dlg">EPA Method 8327</a>: LC–MS/MS for selected PFAS in prepared extracts of aqueous and solid matrices.</li><li><a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/preparing-diverse-sample-matrices-for-epa-method-1633">EPA Draft Method 1633</a>: The emerging benchmark for PFAS in non-aqueous matrices—aqueous, solid, biosolids, and tissue—quantifying up to 40 PFAS.</li></ul>All of these methods designate LC–MS/MS, specifically LC coupled to triple quadrupole or tandem-in-time platforms operating in negative electrospray ionization mode with multiple reaction monitoring (MRM), as the required or recommended analytical technique. PFAS analysis is, at its core, an LC–MS/MS problem.<h4>The Sample Preparation Bottleneck</h4>Chemists who have worked with PFAS methods understand the particular demands they place on sample preparation. The ubiquity of<a target="_blank" rel="noopener noreferrer" href="https://blog.organomation.com/blog/tackling-pfas-contamination-practical-insights-from-epa-537.1-method-development"> PFAS in laboratory materials</a>—PTFE tubing, some SPE sorbents, standard bench supplies—means that blank contamination control is as analytically demanding as the detection itself. EPA 537.1 requires that sample volumes of approximately 250 mL be extracted and reconstituted in as little as 1 mL, creating a 250:1 concentration factor that can expose even trace contamination in the sample processing chain. The installation of a delay column between the LC pump and autosampler to prevent instrument background interference is now standard practice.This is precisely where robust, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5385">inert nitrogen evaporation </a>systems earn their keep. PFAS workflows that use nitrogen-assisted evaporation to concentrate extracts prior to reconstitution benefit from materials that avoid PTFE and other fluoropolymers that can leach PFAS background—a consideration Organomation addresses in its concentration system designs.The analytical community is also moving beyond targeted PFAS analysis. High-resolution accurate mass (HRAM) spectrometry via Orbitrap technology, paired with non-targeted screening workflows, is gaining traction for the identification of the more than 5,000 currently catalogued PFAS compounds and the novel structures that continue to emerge. LC–MS/MS remains the quantitative gold standard; HRAM provides the discovery layer.<h3>Technological Trends Reshaping the LC–MS/MS Workflow</h3><h4>Artificial Intelligence and Automated Data Interpretation</h4>The datasets generated by modern tandem MS platforms—particularly in omics applications—are too large and too complex for conventional manual review. AI-driven spectral deconvolution, automated peak integration, and AI-assisted hypothesis generation are now embedded in the software suites accompanying leading instruments. <a target="_blank" rel="noopener noreferrer" href="https://www.agilent.com/about/newsroom/presrel/2022/17feb-gp22004.html?srsltid=AfmBOop3warRIaEojXM2YyMML6RXfMIDzE-Wm0h-SiKkkocBeeET2m7u">Agilent’s acquisition of Virtual Control’s ACIES </a>software specifically to automate LC–MS and GC–MS data analysis is emblematic of this direction.For laboratory managers, AI integration means smaller specialized teams can operate high-throughput multi-analyte workflows—but it also means that the front-end sample preparation must be even more reproducible, since algorithmic interpretation amplifies inconsistencies introduced upstream.<h4>Online SPE Coupling and “Chromatography Without Walls”</h4>A significant trend is the integration of solid-phase extraction directly into the HPLC flow path—so-called online SPE–HPLC coupling. Systems that combine extraction and chromatographic separation in a single analytical instrument reduce manual transfer steps, minimize the risk of sample loss or contamination, and dramatically increase throughput. For analytes at very low concentrations, online SPE provides the on-column concentration capability that traditional offline preparation achieves with manual evaporation steps.That said, offline sample preparation—including <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/article/5392">nitrogen-assisted evaporation</a> under controlled conditions, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2407">liquid–liquid extraction</a>, and protein precipitation—retains significant advantages in flexibility, matrix handling, and the ability to process sample volumes that exceed online system capacity. The two approaches are increasingly complementary rather than competitive in well-designed analytical laboratories.<h4>High-Purity Solvents and Reference Materials</h4>As detection limits push further into the femtogram range and regulatory methods demand demonstrable blank performance, the quality of analytical consumables—mobile phase solvents, derivatization reagents, reference standards—has moved from background consideration to front-of-mind. Method validation in regulated environments now routinely requires vendor certification of solvent purity at a level that directly interfaces with instrument performance.<h3>The Ever-Present Need for Sample Evaporation</h3>As LC–MS/MS methods push detection limits lower, the analytical burden shifts increasingly upstream. The quality of the concentration, cleanup, and reconstitution steps preceding injection determines whether the instrument’s theoretical sensitivity is achievable in practice.Several specific developments are particularly relevant:<ul><li>ADC and gene therapy characterization workflows require gentle, low-temperature evaporation that preserves protein structure and prevents aggregation prior to LC–MS/MS. Nitrogen evaporation under controlled conditions is the preferred approach.</li><li>PFAS trace analysis demands evaporation systems constructed from PFAS-inert materials, with rigorous attention to avoiding fluoropolymer surfaces throughout the sample path.</li><li>High-throughput pharmaceutical QC driven by reshoring demands parallel processing capability—multi-position evaporators that maintain consistent flow and temperature across all positions simultaneously.</li><li>Multi-omics and metabolomics workflows generate large sample batches that benefit from automated, walk-away evaporation with programmable endpoints to ensure reproducible final volumes across a cohort.</li></ul>Tandem chromatography–mass spectrometry is not merely growing; it is becoming structurally embedded in the analytical workflows of every major regulated industry. The convergence of biopharma complexity, PFAS regulatory mandates, AI-enabled data analysis, and pharmaceutical reshoring is creating a multi-year demand cycle that will require laboratories to invest not only in instruments, but in the entire sample preparation ecosystem that makes those instruments perform.For analytical chemists, the practical takeaway is this: as mass spectrometry sensitivity continues to advance, the sample preparation step becomes the binding constraint on method performance. Whether you are developing a new PFAS method to meet EPA 1633, characterizing an ADC’s drug-to-antibody ratio, or running a 500-sample metabolomics cohort overnight, the reliability and cleanliness of your concentration and cleanup workflow determines the quality of every data point that follows.&nbsp;

The Continued Rise of Tandem Chromatography–Mass Spectrometry

News from LabRulezLCMS Library - Week 27, 2026

🎤Dr. Christopher Reid (Professor of Chemistry and Biochemistry at Bryant University in Rhode Island)In this episode of Concentrating on Chromatography, host Dave Oliva sits down with Chris Reid to explore how chemical biology and LC-MS are being used to tackle one of the most urgent global challenges: antimicrobial resistance.As antibiotic resistance continues to rise—and new drug development struggles to keep pace—researchers are looking beyond traditional approaches. Instead of targeting how bacteria build their cell walls, Chris’s work focuses on how they break them down, opening the door to entirely new antimicrobial strategies.<h4>What You’ll Learn in This Episode:</h4><ul><li>Why antimicrobial resistance is accelerating globally</li><li>What peptidoglycan is and why it’s essential to bacterial survival</li><li>How targeting cell wall degradation differs from traditional antibiotics</li><li>The strategy behind designing small molecule probes and inhibitors</li><li>How LC-MS is used to analyze peptidoglycan fragments and enzyme activity</li><li>Key analytical challenges: complex mixtures, low-abundance species, and structural similarity</li><li>The importance of sample preparation and reproducibility in LC-MS workflows</li><li>How this research could lead to new antibiotic targets</li></ul><h3>Video Transcription</h3><h4>The Growing Challenge of Antibiotic Resistance</h4>According to Reid, antibiotic resistance is increasing across a broad spectrum of bacterial pathogens that were once readily treated with existing therapies. In some cases, clinicians must now rely on only a handful of last-line antibiotics, while resistance is also rising in diseases such as tuberculosis.One of the major obstacles is the limited commercial incentive to develop entirely new antibiotics. Because bacterial resistance can emerge relatively quickly after a drug reaches the market, pharmaceutical companies often favor modifying existing antibiotics or combining them with resistance-modifying agents rather than investing in completely new drug classes. As a result, genuinely novel antibacterial targets remain urgently needed.<h4>Why the Bacterial Cell Wall Remains an Attractive Target</h4>The bacterial cell wall consists primarily of peptidoglycan, a highly cross-linked polymer that provides structural integrity, maintains cell shape, and enables bacterial growth and division.Many widely used antibiotics—including the β-lactam antibiotics such as penicillins—target enzymes responsible for synthesizing or cross-linking peptidoglycan. These pathways have proven highly successful therapeutic targets because peptidoglycan is unique to bacteria and absent from human cells, minimizing unwanted effects on the host.However, most existing antibiotics target only specific stages of peptidoglycan biosynthesis. Reid's research explores another part of this complex pathway: enzymes responsible for degrading the carbohydrate backbone of peptidoglycan during normal bacterial growth and remodeling. These enzymes may represent an underexplored class of antimicrobial targets capable of overcoming existing resistance mechanisms.<h4>Targeting the Glycan Backbone</h4>A key advantage of focusing on the carbohydrate backbone is its remarkable conservation across both Gram-positive and Gram-negative bacteria.Whereas the peptide components of peptidoglycan vary considerably between bacterial species—and frequently acquire mutations associated with antibiotic resistance—the glycan backbone remains highly conserved and tolerates relatively few structural modifications.This biological constraint makes enzymes acting on the glycan backbone particularly attractive targets. Reid's group developed a series of small-molecule probes and inhibitors designed to recognize enzymes known as N-acetylglucosaminidases, which cleave glycosidic bonds within peptidoglycan and generate soluble degradation products.Rather than beginning with purified enzymes, the researchers adopted a top-down phenotypic screening strategy. Candidate compounds were first evaluated for their ability to inhibit bacterial growth before progressively narrowing the list of potential molecular targets through genetic studies, microscopy, enzyme assays, and biochemical characterization. This iterative workflow ultimately identified compounds capable of inhibiting the desired enzyme class while simultaneously providing valuable chemical probes for studying bacterial cell wall biology.<h4>LC-MS as a Central Analytical Tool</h4>Liquid chromatography coupled with mass spectrometry plays a central role throughout the project by enabling detailed characterization of structural changes occurring within peptidoglycan after bacterial cells are treated with candidate inhibitors.Because intact peptidoglycan is an insoluble polymer, sample preparation begins with isolation of the bacterial cell wall through detergent extraction and differential centrifugation. Additional purification steps remove proteins, nucleic acids, and teichoic acids before enzymatic digestion converts the insoluble material into soluble fragments suitable for chromatographic analysis.The resulting digest is analyzed by LC-MS to examine changes in the distribution of peptidoglycan fragments. Chromatographic retention times provide an immediate indication of changes in cross-linking, with larger oligomers such as trimers and tetramers generally eluting later than monomeric fragments. Mass spectrometry then confirms the identity of these fragments by measuring their intact molecular masses, while tandem MS experiments can provide further structural information when required.<h4>Sample Preparation Determines Data Quality</h4>Reid emphasized that sample preparation represents one of the most critical—and challenging—stages of the entire workflow.Because peptidoglycan analysis involves multiple purification, digestion, and reduction steps, even minor procedural differences between samples can introduce analytical artifacts that complicate biological interpretation.Maintaining strict consistency throughout sample preparation is therefore essential. Appropriate controls must accompany every experiment, ensuring that observed chromatographic and mass spectrometric differences truly reflect biological responses rather than experimental variability. The complexity of bacterial cell wall composition further increases the analytical challenge, as subtle differences in amino acid substitutions and low-abundance cross-linked species can complicate LC-MS data interpretation.<h4>Chemical Biology for Future Antibiotic Discovery</h4>Although the identified compounds may eventually serve as starting points for antibiotic development, Reid views them primarily as chemical biology tools.By selectively inhibiting individual enzymes, these probes allow researchers to investigate previously unexplored aspects of bacterial cell wall remodeling that cannot easily be studied using classical genetic approaches alone.The research team is now expanding this strategy by combining their probes with proximity-labeling proteomics and mass spectrometry, aiming to map protein interaction networks associated with bacterial cell wall degradation. Such studies may reveal entirely new antibacterial targets and provide deeper insight into the biological processes governing bacterial growth and division.Ultimately, the work illustrates how integrating synthetic chemistry, microbiology, molecular biology, and advanced LC-MS can accelerate the search for innovative therapeutic strategies against antimicrobial resistance. As existing antibiotics become progressively less effective, multidisciplinary approaches such as these may play an increasingly important role in identifying the next generation of antibacterial targets.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

 Fighting Antibiotic Resistance with LC-MS: Targeting Bacterial Cell Walls

Article

Application

Academy

Video

Scientists

Interview

Poster

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Phenomenex

Thermo Fisher Scientific

PerkinElmer

Restek Corporation

VWR/Avantor

Waters Corporation

Presented in a Q&amp;A format, this session of our LC learning series will explore some of the most common issues/problems encountered in the HPLC lab. As the most important diagnostic tool for HPLC is monitoring the pump pressure, several examples of pressure issues will be discussed. Other problems, such as retention time and peak area irreproducibility, and detector baseline noise or drift will be also presented.
The aim of this session is to provide some basic troubleshooting fundamentals to build confidence in recognizing when issues are occurring and how to resolve them to improve instrument uptime and laboratory productivity.
<blockquote>
Presenter: Pamela A. Perrone (Senior Principal LC Technical Education, PerkinElmer)
</blockquote>
<blockquote>
Pam has been with PerkinElmer for almost 39 years. She had the opportunity to work as a summer intern and was offered full-time employment after completing her Ph.D. in Analytical Chemistry at the University of Rhode Island. Currently Pam is in the role she finds most fulfilling and challenging which is as the global support and trainer for both service and customers for LC and chromatography data handling. To help someone learn and be successful in their job is very rewarding.
</blockquote>
<blockquote>
Pam has a passion for three things (besides LC, of course!): her family, the UConn women’s basketball team and Broadway. She believes there is a Broadway song that fits almost every occasion.
</blockquote>
<blockquote>
Presenter: Jamie Foss (Product Manager – Liquid Chromatography, PerkinElmer)
</blockquote>
<blockquote>
Jamie Foss is the Liquid Chromatography Product Manager for PerkinElmer. Prior to this role, he was a Sr. Application Scientist developing strategic applications in support PerkinElmer’s LC and LC-MS product portfolio. He has developed a wide variety of applications across food, environmental, industrial, forensics and cannabis. Prior to joining PerkinElmer in 2016, he spent 4 years as a forensic chemist for the State of Maine where he focused on the analysis of controlled substances and clandestine laboratory investigation.
</blockquote>

PerkinElmer: Liquid Chromatography 2022 Learning Series

Basics of HPLC Troubleshooting

Presented in a Q&A format, this session of our LC learning series will explore some of the most common issues/problems encountered in the HPLC lab.

The HPLC instrument has been at the heart of many analytical laboratories for several decades now. Quite often analysts may be introduced to the concept of chromatography through the course of study, but it’s much less likely that the mechanics of the system will have been explored in detail. Because of this, it can be a bit daunting approaching problem solving with these instruments.
In this presentation, we’ll be walking you through an overview of the processes involved with basic HPLC instrumentation. From there we’ll examine in a greater depth how each component of a HPLC system comes together to provide the analysis you may be looking for, looking at the finer mechanical details of what is taking place, and offering tips along the way to keep your system running smoother for longer.
<h5>This webinar aims to:</h5>
<ul>
<li>Provide a general overview of what an HPLC Instrument is</li>
<li>Look in greater depth at individual sections of the HPLC instrument to describe how they function</li>
<li>Offer some advice on how to look after your instrument to keep it running well for longer</li>
</ul>

Restek: LC Hardware Troubleshooting part 1

LC Hardware Troubleshooting part 1

In this presentation, we’ll be walking you through an overview of the processes involved with basic HPLC instrumentation.

<ul>
<li>Choosing the right column</li>
<li>Preparation of the mobile Phase</li>
<li>Why column protection is so important</li>
<li>How column care can affect your method development</li>
</ul>
<h5>Who Should Attend:</h5>
<ul>
<li>Analysts/Scientists routinely working with HPLC methods/method development.</li>
</ul>

Phenomenex: 5 Basic Chromatography Tools for LC or LC-MS Method Development

5 Basic Chromatography Tools for LC or LC-MS Method Development

Learn about the 5 key tools that help with HPLC method development including.

Chromatography Tools for LC or LC-MS Method Development

The analysis of mineral oil saturated hydrocarbons (MOSH) and mineral oil aromatic hydrocarbons (MOAH) in food samples is a challenging application. Don´t miss this opportunity to ask our experts all your questions regarding the fully automated LC/GC workflow for MOAH/MOAH analysis.
We start with a brief introduction where we talk about upcoming changes in the legal requirements for MOSH/MOAH analysis. The remaining time is fully dedicated to your questions.
There are three ways to submit your questions:
<ul>
<li>Fill out the box on the webinar registration form</li>
<li>For more detailed questions, you can email us at: analyze.eu@thermofisher.com</li>
<li>Ask your questions on the day using the chat function during the live session</li>
</ul>
Of course you are welcome to join even if you don´t have a specific question, so you can pick up useful information and build up expertise.
<blockquote>
Presenter: Jeroen Weyts (SampleQ Analytical Support GC-MS, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Presenter: Jorn Hofsteenge (SampleQ Analytical Support GC)
</blockquote>
<blockquote>
Presenter: Inge de Dobbeleer (Sample Q Account Manager)
</blockquote>
<blockquote>
Presenter: Petra Gerhards (Regional Marketing Manager for GC &amp; GC-MS, EMEA, Thermo Fisher Scientific)
</blockquote>

Thermo Fisher Scientific: Ask-the-experts session on MOSH/MOAH analysis

Ask-the-experts session on MOSH/MOAH analysis

Don´t miss this opportunity to ask our experts all your questions regarding the fully automated LC/GC workflow for MOAH/MOAH analysis.

Analyzing polar molecules presents a unique challenge for chromatographers. These molecules span the varying markets: from Polar pesticides in food to Non-steroidal anti-inflammatory drugs to highly polar sugars and amino acids. Conventional HPLC stationary phases like C18 often do not provide adequate retention and separation of such highly polar compounds. Consequently, chromatographers are forced to step outside of their comfort zone and start exploring polar chemistries. Both reverse phase polar columns as well as hydrophilic stationary phases are utilized for solving this problem.
This webinar will not focus on specific applications, but we will try to present general guidelines on how to choose the right separation mode (HILIC or RP). Working down a checklist, we will discuss aspects that have to be taken into consideration when developing new polar molecule separations.
<h5>By attending this webinar you will learn:</h5>
Find the best column to retain and separate polar analytes, focusing on HILIC and polar RP.
<ul>
<li>How to choose between RP and HILIC based on analyte solubility and sample solvent.
</li>
<li>How the right separation mode can ensure reliable detection of your sample.
</li>
<li>3x faster analysis using Poroshell Chiral vs TPP Competitor columns.
</li>
<li>Separate a wide variety of analytes on Poroshell Chiral columns. Keep fewer chiral columns in the lab.
</li>
<li>No need to use normal phase solvents or dedicated normal phase systems for chiral separations.
</li>
</ul>
<blockquote>
Presenter: Scott Bollen (Business Development Manager EMEA, Agilent Technologies)
</blockquote>
<blockquote>
Scott specializes in small molecule LC columns, ranging from HPLC to UHPLC. Scott has worked at Agilent for 17 years. He started as a technical support manager, and now supports new LC products in R&amp;D as well as the entirety of the existing small molecule LC column portfolio in business development.
</blockquote>

Agilent Technologies: HPLC Separation Solutions for Polar & Chiral Analysis

HPLC Separation Solutions for Polar & Chiral Analysis

This webinar will not focus on specific applications, but we will try to present general guidelines on how to choose the right separation mode (HILIC or RP).

AQbD or Analytical Quality by Design is an approach to analytical method development that “starts with the end in mind”.
Regulators welcome this science and risk-based approach as described in several guidelines from ICH, USP, and BP. Using the preferred language of regulators when filling applications for both small and large molecules, synthetic or biological drugs can significantly reduce the time-to-market.
Learn about general concepts and approaches to AQbD that are outlined in the upcoming ICH Q14 and USP &lt;1220&gt; chapters and how industry leaders and Waters are tackling these exciting workflows guaranteed to reduce risk and produce robust methods across your organization. 
Join us on Tuesday, November 29 and hear from experts in the Pharma arena to receive an update on the guidance, and the impact for the industry, an example for the phase-appropriate implementation of AQbD method development and a how to mitigate risk using the MaxPeak High Performance Surface. 
Followed by a live panel discussion with all the speakers. So have your questions ready!
<h3>Confirmed Speakers on 29 Nov:</h3>
<h4>Analytical Procedure Development &amp; Validation – ICH Q14, ICH Q2 (R2) &amp; USP &lt;1220&gt;</h4>
 
<blockquote>
Presenter: Phil Borman (Director and Senior Fellow, GSK)
</blockquote>
<blockquote>
Phil Bormanis a fellow of the Royal Society of Chemistry with over 26 years of experience in the pharmaceutical industry having obtained a Masters in Chemistry from Manchester University, a Masters in Applied Statistics from De Montfort (Leicester) University and a Doctorate in Sciences for his work in pioneering and developing QbD approaches for analytical procedures (also from De Montfort University).
</blockquote>
<blockquote>
Phil is currently a Director and Senior Fellow at GlaxoSmithKline where he is accountable for the ongoing development and implementation of Quality by Design. Phil pioneered the adaptation of QbD principles to Analytical procedures and has published widely in the field of Analytical Chemistry. He currently co-leads the EFPIA ICH Q2(R2)/Q14 support team as well as being vice-chair of the USP Measurement and Data Quality Expert Committee and member of the BP (MHRA) Analytical Quality by Design Working party.
</blockquote>
<h4>Development of analytical methods based on the aQbD principles to support pharmaceutical development, commercialization and supply</h4>
<blockquote>
Presenter: Jinjian Zheng (Sr. Principal Scientist, Merck)
</blockquote>
<blockquote>
Dr. Jinjian Zheng earned his Ph.D. degree from The University of Tokyo in 1999, and joined Ames-Laboratory, Iowa State University as a postdoc in 2000. He joined Schering-Plough/ Merck in 2003, and is currently a Sr. Principal Scientist at Analytical Chemistry in Development and Supply – Analytical Commercialization Technology.
</blockquote>
<blockquote>
During his tenure at Merck, Jinjian has served on different roles within Merck across development, commercialization and supply areas. He has established himself as a chromatography SME, and has been promoting aQbD method development at Merck using advanced tools such as chromatography simulation and DOE experimentation.
</blockquote>
<blockquote>
Jinjian has published 20+ articles in peer reviewed journals, and has given numerous presentations on aQbD method development. He is currently leading the analytical development efforts at Merck to support nitrosamine risk assessment and testing.
</blockquote>
<h4>Mitigating Risks Associated with Undesired Analyte-Metal Interactions</h4>
<blockquote>
Presenter: Pankaj Aggarwal (Associate Principal Scientist, Merck)
</blockquote>
<blockquote>
Pankaj has a PhD in analytical chemistry with over 7+ years of pharmaceutical industry supporting API and DP development across different modalities. Currently, He is working as Associate Principal Scientist at Merck and a scientific supervisor implementing predictive and digital solution for workflow optimization leading to operation excellence and accelerated drug development. Pankaj is passionate about lab automation/digital data analytics and helping teams applying in-silico tools to fundamentally understand LC method performance.
</blockquote>
<h4>Moderator for the Event Day 1</h4>
<blockquote>
Presenter: Fadi Alkhateeb (Senior Scientist, Waters Corporation)
</blockquote>
<blockquote>
Dr. Fadi Alkhateeb is a Senior Scientist in the Scientific Operations Department at Waters Corporation HeadQuarters in Milford, MA USA. He joined Waters in 2017 and since then he has been mainly focusing on exploring various approaches for analytical method development for pharmaceutical drugs. Prior to joining Waters, he was a postdoctoral fellow at the University of Calgary (Calgary, AB, Canada), where he did research at Alberta Sulphur Research, one of North America&#39;s leading Sulphur research institutes.
</blockquote>
<blockquote>
He received his PhD from the University of Calgary, focusing on the development of novel, rapid separation and sample preparation techniques for the analysis of a wide range of chemical compounds. Dr. Alkhateeb published several peer-reviewed articles in top analytical journals.
</blockquote>

AQbD Symposium - Day 1 - Concepts and Approaches for Enhanced Method Development

An update on the guidance, and the impact, the phase-appropriate implementation of AQbD MD and the MaxPeak High Performance Surface. 

Concepts and Approaches for Enhanced Method Development

AQbD or Analytical Quality by Design is an approach to analytical method development that “starts with the end in mind”.
Exploring experimental conditions and using statistical tools to search for a suitable set of conditions until the method is stable and quality goals are met, are the key success factors for the enhanced approach.
Method development is step one, guaranteeing a quality assay requires stress testing and monitoring verified and validated methods. Learn how these easily implemented tools can help guarantee consistent quality and prevent unreliable results.
Join us on Wednesday, November 30 and hear from experts in the Pharma arena on the application of AQbD for compendial methods, how to apply Method performance monitoring, and application of AQbD in the European Pharmacopeia.
Followed by a live panel discussion with all the speakers. So have your questions ready!
<h3>Confirmed Speakers on 30 Nov:</h3>
<h4>AQbD principles application to compendial procedures and across the procedure life cycle</h4>
<blockquote>
Presenter: Amanda Guiraldelli (Scientific Affairs Manager, US Pharmacopeia)
</blockquote>
<blockquote>
Amanda Guiraldelli has been with USP since 2012 and holds the position of scientific affairs manager. She is also the scientific liaison for the USP chapters &lt;1220&gt; Analytical Procedure Life Cycle and &lt;1039&gt; Chemometrics in the compendial science group-general chapters. Previously, Amanda worked as senior scientist at the USP reference standard laboratory for 8 years with characterization of compendial standards.She is visiting professor at the University of Campin as (UNICAMP) Brazil at the Institute of Chemistry and is a frequent speaker and instructor on topics related to analytical procedure life cycle and Analytical Quality by Design (AQbD). Amanda is specialist in chromatography, mass spectrometry and chemometrics and has more than 12 years of experience in pharmaceutical R&amp;D areas.
</blockquote>
<blockquote>
Prior to joining USP, she was R&amp;D scientist in a Brazilian pharmaceutical industry and visiting scientist at TU Berlin in Germany and Leiden University in Netherlands (Center for Proteomics and Metabolomics) working on proteins characterization by LC-HRMS and procedure development using UHPLC-HRMS. Amanda is graduated in pharmacy biochemistry and holds a Ph.D. in analytical chemistry from the University of São Paulo (metabolomics by UHPLC-HRMS, GC-MS and 1H NMR and chemometrics).
</blockquote>
<h4>Replacement of a viral content method for a more robust anion exchange chromatography method</h4>
<blockquote>
Presenter: Dawn Kernaghan (Principal Scientist, AstraZeneca)
</blockquote>
<blockquote>
Dawn received a Masters in Chemistry in 2002 from University of Maryland. After graduating, she got her first work experience in academia performing muscular dystrophy research. She joined AstraZeneca, formerly Medimmune, in 2006 where she worked in analytical method development. While in development shefocused in the areas of immunoassays, new technology evaluations and automation. In 2016, she moved into Operations where she now works on the validation and technology transfer of analytical methods for commercial.
</blockquote>
<h4>Benefits of using 2.x µm columns on UHPLC systems for AQbD development</h4>
<blockquote>
Presenter: Andrea Gheduzzi (Southern Europe Pharma Market Dev. Manager, Waters Corporation)
</blockquote>
<blockquote>
Andrea has spent more than 30 years in the chromatography field. Across his career he had various roles, service engineer, chromatography lab position, and technical application support manager. He has mainly been dealing with pharma accounts, also supporting LC method development activities using DoE/QbD approaches. In his role as Pharma Business Development Manager at Waters he has further expanded his expertise in AQbD and related applications.
</blockquote>
<h4>Moderator for the Event Day 2</h4>
<blockquote>
Presenter: Arjan Timmerman (Waters Corporation)
</blockquote>

AQbD Symposium - Day 2 - Developing Fit for Purpose Methods for the Complete Life Cycle

Join us and hear how to apply Method performance monitoring, and application of AQbD in the European Pharmacopeia.

Developing Fit for Purpose Methods for Complete Life Cycle

The HPLC instrument has been at the heart of many analytical laboratories for several decades now. Quite often analysts may be introduced to the concept of chromatography through the course of study, but it’s much less likely that the mechanics of the system will have been explored in detail. Because of this, it can be a bit daunting approaching problem solving with these instruments.
In the second webinar of this series, we will discuss how problems with your instrument may affect your chromatographic separations. Alongside this, we look to see where instrument results may be highlighting issues, and using this to narrow down potential causes of issue. Along the way there will be practical tips for things you can do to minimise potential faults.
This presentation aims to:
<ul>
<li>Highlight how various hardware faults may impact chromatographic performance</li>
<li>Show why instrument faults can occur and offer solutions to these issues</li>
<li>Offer steps for troubleshooting through issues to determine issues</li>
</ul>
<blockquote>
Presenter: John Gallant (LC Specialist, Restek Corporation)
</blockquote>

Restek: LC Hardware Troubleshooting part 2

LC Hardware Troubleshooting part 2

we will discuss how problems with your instrument may affect your chromatographic separations. 

Wonder why there’s a need for peptide mapping? Is it difficult to obtain a charge variant analysis? Need tips when cutting your protein? Join us as we review key fundamentals in bio-LC workflow applications – learn about methods and the columns or consumables that accompany these areas to complete your research with ease.
This webinar will review these core areas:
<ul>
<li>Peptide mapping</li>
<li>Charge variants</li>
<li>Protein applications</li>
<li>Oligos and gene therapies</li>
</ul>
This webinar is for you, if you&#39;re
<ul>
<li>New, and would like to know where to start</li>
<li>Not so familiar with consumables and need guidance</li>
<li>Well-seasoned researcher who wants to gain new insights on top consumables in the market!</li>
</ul>
<blockquote>
Presenter: Kaja Gleerup
</blockquote>
<blockquote>
Kaja’s vast technical knowledge for 15+ years encompasses many chromatography facets, enabling her to uniquely decipher solutions within different chemistries. She worked in a GMP environment manufacturing protein therapeutics, to technical support, then commercial, and most recently in product marketing. Her expertise lies in supporting scientists in method development/optimization, aiding with theory and applications for specific or groups of analytes at multiple manufacturers.
</blockquote>

Basics in Bio-LC

Key fundamentals in bio-LC workflow applications – methods and the columns or consumables that accompany these areas.

Key Learning Points:
<ul>
<li>Introduction &amp; Theory of Hydrophilic interaction chromatography (HILIC)</li>
<li>HILIC Stationary Phases and Interaction Mechanisms</li>
<li>HILIC Mobile Phase and Method Development</li>
<li>Advantages &amp; Disadvantages of HILIC</li>
</ul>
<blockquote>
Presenter: Jeffery Moran, PhD (Chief Executive Officer, PinPoint Testing)
</blockquote>
<blockquote>
Jeffery Moran, Ph.D. is an analytical toxicologist with over 25 years of experience in analytical chemistry, metabolomics, and human biomarkers.  Currently, Dr. Moran is the CEO of PinPoint Testing, LLC and faculty in the College of Medicine at the University of Arkansas for Medical Sciences. The Mission of PinPoint Testing, LLC is to “Make Analytical Toxicology Easy” through innovative ToxBox® test kits and solutions.  Dr. Moran’s career spans many facets that include medicine, public health, environmental, food, and industrial hygiene.  His research primarily focuses on the detection and mechanisms of environmental toxicants and xenobiotics. His recent work includes the detection and characterization of synthetic cannabinoids (SCBs), which emerged as a major drug of abuse. Dr. Moran’s passion is creating sustainable solutions for analytical testing laboratories.  
</blockquote>

Phenomenex: A Lean Approach for Assessing LC column Performance During Validation 

A Lean Approach for Assessing LC column Performance During Validation 

Introduction & Theory of Hydrophilic interaction chromatography (HILIC), Stationary Phases, Mobile Phase and Method Development, Advantages & Disadvantages.

LCMS webinars focusing on HPLC - page 44